SCHEMBL6801328

SCHEMBL6801328

c1ccc(-c2cc(OCc3cccnc3)c3sccc3n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.54
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
PDE3B Q13370 2/20 0.47
PDE3A Q14432 2/20 0.47
HTR1A P08908 1/20 0.45
DRD2 P14416 1/20 0.45
CYP11B1 P15538 4/20 0.45
CYP11B2 P19099 4/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CYP19A1 P11511 2/20 0.44
ADORA2A P29274 3/20 0.43
ADORA2B P29275 3/20 0.43
PDPK1 O15530 1/20 0.43
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793662 0.87 IKBKB (0.50) IKBKBPDE4APDE4BPDE4CPDE4D
SCHEMBL4848138 0.81 IKBKB (0.61) IKBKBHTR1ADRD2CYP11B1CYP11B2
SCHEMBL4847192 0.74 ADORA2A (0.44) IKBKBPDE4APDE4BPDE4CPDE4D
SCHEMBL4847212 0.73 BRD4 (0.39) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL4855811 0.72 SYK (0.46) GCK
SCHEMBL4857946 0.68 MET (0.36) IKBKBPDE4APDE4BPDE4CPDE4D
SCHEMBL4849634 0.66 MAPT (0.45) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL7447577 0.66 MEN1 (0.47) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL8140217 0.65 ADORA2A (0.50) MEN1KMT2AADORA2AALDH1A1KDM4E
SCHEMBL7311175 0.65 MAPK1 (0.65) IKBKBHTR1ADRD2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828329-B2 Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders NEUROGEN CORPORATION 2004-12-07 US claimed